الفهرس | يوجد فقط 14 صفحة متاحة للعرض العام |
المستخلص ABSTRACT Backround: HCV infection is closely associated with liver fibrosis, a major risk factor related to liver cirrhosis and hepatocellular carcinoma. Aim: To evaluate the levels of sCD163, MMP9, and CK18 as noninvasive biomarkers for different grades of liver fibrosis in Egyptian chronic hepatitis C patients. Subjects: Eighty eight subjects were divided into thirteen healthy subjects as control group and seventy five HCV patients with liver fibrosis were divided into three groups based on their fibrosis grade: group 2 (no liver fibrosis, F0), group 3 (liver fibrosis, F1-F2), and group 4 (liver fibrosis, F3-F4). Methods: The ELISA technique was used to assess the levels of direct serum indicators sCD163, MMP9, CK18, and AFP. A complete blood count, serum ALT, AST, albumin, total bilirubin, and INR were measured. In addition, as indirect biomarkers, the FIB-4 score and the AST/ALT Ratio (AAR) were reported. Results: Serum sCD163, MMP9 and AFP levels showed a significant increase in G2 (F0) patients ,this increase was augmented in parallel with the grade of fibrosis to reach to highly significant increase in G3 (F1-F2) and G4 (F3-F4) compared to control group .Serum CK-18 levels reported remarkable highly significant increase in all groups compared to control group. FIB-4 and AAR showed a significant increase in all HCV patients, compared to control group. Conclusion: The current data supported that MMP9 was more specific biomarker for grades of fibrosis (F1 and F2), whereas serum sCD163 was more specific biomarker for grades of fibrosis (F3 and F4). |